Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia
(CELESTE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine which insomnia treatments are most effective and safe for individuals with menopause-related sleep issues. Participants will test one of three options: trazodone (a medication often used for sleep disorders), daridorexant (a medication for insomnia), or a cognitive behavioral therapy program, each lasting 12 months. The trial specifically targets those in peri- or early menopause who began experiencing sleep difficulties during this time. Participants will track their sleep using a Fitbit and a diary, with a combination of in-person and virtual check-ins. As a Phase 4 trial, the treatments are already FDA-approved and have proven effective, helping to understand their benefits for more patients.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it excludes people who regularly use hypnotics more than 2 nights a week or those using strong CYP3A4 inhibitors or drugs that prolong the QTc interval. It's best to discuss your current medications with the trial team.
What is the safety track record for these treatments?
Research shows that cognitive behavioral therapy for insomnia (CBT-i) is generally safe for menopausal women. Studies have found that it significantly improves sleep quality and reduces insomnia severity, with no major safety issues reported.
The FDA has approved daridorexant for treating insomnia in adults. Research indicates it helps menopausal women fall asleep and stay asleep, with a good safety record in studies, suggesting it is well-tolerated.
Although the FDA has approved trazodone for depression, it is often used to treat insomnia. A review of studies found it effective for insomnia with little to no risk for most people.
Overall, research suggests that all three treatments—CBT-i, daridorexant, and trazodone—are safe options for treating insomnia in menopausal women.12345Why are researchers enthusiastic about this study treatment?
Researchers are excited about these treatments for menopause-related insomnia because they offer diverse approaches to tackling sleep issues. Cognitive behavioral therapy for insomnia (CBT-i) is unique as it addresses the root causes of insomnia through behavioral changes, providing a non-drug option that can have long-lasting benefits. Trazodone, an antidepressant often used off-label for insomnia, is included for its sedative effects, offering a familiar yet effective oral option that can be adjusted for individual needs. Meanwhile, Daridorexant stands out with its novel mechanism of action as a dual orexin receptor antagonist, which targets the brain pathways responsible for wakefulness, potentially leading to more natural sleep without the grogginess associated with some other sleep aids.
What evidence suggests that this trial's treatments could be effective for menopause-related insomnia?
This trial will compare three treatments for menopause-related insomnia: cognitive behavioral therapy for insomnia (CBT-i), daridorexant, and trazodone. Research has shown that CBT-i greatly improves sleep quality and reduces insomnia symptoms in menopausal women, leading to moderate to large improvements in sleep issues and quality of life. Studies have found that daridorexant helps with falling asleep, staying asleep, and functioning during the day for menopausal women with insomnia, noticeably improving sleep and increasing overall sleep time. Trazodone, often used for insomnia, has effectively improved sleep with minimal risk in many cases and is commonly used off-label for this purpose, indicating its potential benefits for sleep problems. All three treatments in this trial show promising results in addressing menopause-related insomnia symptoms.26789
Who Is on the Research Team?
Suzanne Bertisch, MD, MPH
Principal Investigator
Brigham and Women's Hospital
Are You a Good Fit for This Trial?
This trial is for peri- and post-menopausal women experiencing insomnia. Participants will be diverse in socio-demographic backgrounds, menopause stages, and may have related conditions like sleep apnea or mood disturbances. Details on specific inclusion and exclusion criteria are not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive one of the three insomnia therapies (CBT-I, trazodone, or daridorexant) for 12 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Cognitive behavioral therapy for insomnia (CBT-i)
- Daridorexant
- Trazodone
Trial Overview
The study compares the effectiveness of trazodone, daridorexant (both medications), and cognitive behavioral therapy for insomnia (CBT-i) over a 12-month period with one in-person visit and five virtual check-ins.
How Is the Trial Designed?
3
Treatment groups
Active Control
Participants will be asked to take part in the CBT-i program over the course of 6-9 weeks, with the option of revisiting content throughout the study duration (12 months).
Participants will be asked to take trazodone (oral pill administration) for the duration of the study (12 months), with safety monitoring conducted by study staff throughout the study. Dosage adjustments may occur.
Participants will be asked to take daridorexant (oral pill administration) for the duration of the study (12 months), with safety monitoring conducted by study staff throughout the study.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Brigham and Women's Hospital
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborator
Massachusetts General Hospital
Collaborator
Wake Forest University Health Sciences
Collaborator
University of Utah
Collaborator
Henry Ford Health System
Collaborator
University of Pittsburgh
Collaborator
Citations
The Effectiveness of Cognitive Behavioral Therapy on ...
The results consistently showed that CBT-I significantly improves sleep quality and reduces insomnia severity in menopausal women.
0571 Cognitive Behavioral Therapy for Menopausal Insomnia ...
CBT-MI significantly decreases menopause insomnia severity and improves vasomotor symptoms in midlife women primarily due to attenuating sleep symptoms.
Cognitive Behavioral Therapy for Insomnia in Women ...
Across studies, insomnia symptoms and sleep quality improved with moderate to large effect sizes and achieving clinically significant changes in most studies.
Cognitive Behavioral Therapy for Insomnia and Nocturnal ...
This study aims to develop and evaluate a primary care-based intervention for insomnia and nocturnal hot flashes (nHF) in peri- and postmenopausal women.
Comparing Cognitive Behavioral Therapy for Insomnia, Sleep ...
This study evaluated whether CBTI improves daytime fatigue, energy, self-reported sleepiness, work productivity, and quality of life in postmenopausal women ...
Comparing Cognitive Behavioral Therapy for Insomnia, ...
These data support CBTI and SRT as efficacious treatments to improve nighttime symptoms associated with menopausal insomnia. Yet, insomnia is a 24-hour ...
The Effectiveness of Cognitive Behavioral Therapy on ...
The results consistently showed that CBT-I significantly improves sleep quality and reduces insomnia severity in menopausal women.
Telephone-Based Cognitive Behavioral Therapy for ...
Findings In this randomized clinical trial of 106 women, Insomnia Severity Index scores decreased 9.9 points in women receiving cognitive behavioral therapy ...
In Brief: Telephone-Based CBT for Menopause-Related ...
According to the results published online in the May 24 issue of JAMA Internal Medicine, women in the CBT group were more than 5 times as likely to achieve good ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.